News and Announcements
Analyticas’ AutoStart Burette Listed Through Queensland Health Tender
- Published June 06, 2016 2:41PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
3rd June 2016, ASX Announcement
Analytica (ASX: ALT) is pleased to announce that the AutoStart® infusion system product has been listed on the Queensland Health purchasing schedule. The product was listed by Medical Australia Ltd (ASX: MLA) the Australian sponsor of the device under their Tuta FirstFlow® brand name.
Inclusion in the schedule is a pre-requisite for all public Queensland health facilities to purchase medical devices and other health products. The listing will be reviewed in 2019.
Chairman Dr Michael Monsour said “The listing is another milestone achieved in the commercialisation of the AutoStart infusion system. It allows the product to be purchased by any Queensland Health hospital or health clinic and we aim to list in other states as tenders fall due.”
To view the full announcement, please click on the button below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
